ARWR Arrowhead Pharmaceuticals Inc

$40.45

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending 2025-09-30
Expected on Nov 25, 2025
Report Time: After the Bell
The Whisper Number
$0.00
Consensus Estimate: $0.00
Revenue Estimate: $163.54M

Latest Earnings Insight

Arrowhead Pharmaceuticals is poised for its upcoming earnings release, with the market closely watching its ability to maintain momentum in the RNA interference space. Despite the EPS estimate and whisper number both standing at $0.00, indicating a neutral earnings expectation, the focus will likely be on the company's revenue performance, projected at $163.54 million. This figure is crucial as it reflects Arrowhead's capacity to capitalize on its innovative pipeline and strategic partnerships. With a market cap of approximately $5.7 billion, investors are keen to see how Arrowhead leverages its robust financial position to drive future growth. As the company continues to navigate the competitive biotech landscape, any updates on clinical trials or new collaborations could significantly influence market sentiment and set the tone for its financial trajectory.

Updated On 11/21/2025

About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.

Website: https://arrowheadpharma.com

Sector
TRADE & SERVICES
Industry
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
September
CIK
879407
Address
225 SOUTH LAKE AVENUE, SUITE 1050, PASADENA, CA, US
Valuation
Market Cap
$1.54B
P/E Ratio
nan
PEG Ratio
-1.32
Price to Book
29.35
Performance
EPS
$-5.15
Dividend Yield
—
Profit Margin
0.00%
ROE
-565.00%
Technicals
50D MA
$15.79
200D MA
$20.48
52W High
$30.41
52W Low
$9.57
Fundamentals
Shares Outstanding
137M
Target Price
$45.64
Beta
1.00

ARWR EPS Estimates vs Actual

● Estimated
● Actual

ARWR News & Sentiment

Nov 21, 2025 • Zacks Commentary SOMEWHAT-BULLISH
NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
Nov 18, 2025 • Benzinga NEUTRAL
Why Is Arrowhead Pharma Stock Soaring Tuesday? - Arrowhead Pharma ( NASDAQ:ARWR )
The U.S. Food and Drug Administration ( FDA ) has approved Arrowhead Pharmaceuticals, Inc.'s ( NASDAQ:ARWR ) Redemplo ( plozasiran ) , a small interfering RNA ( siRNA ) medicine, as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome ( FCS ) .
Nov 11, 2025 • Benzinga NEUTRAL
CRISPR Therapeutics' Investigational Gene Therapy Shows Promising Lipid-Lowering Effects In Early Trial - CRISPR Therapeutics ( NASDAQ:CRSP )
On Saturday, CRISPR Therapeutics AG ( NASDAQ:CRSP ) shared Phase 1 data from its ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3.
Nov 04, 2025 • Zacks Commentary NEUTRAL
SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure
Sarepta's Q3 loss and the failure of its key DMD study sent shares tumbling, clouding hopes for its PMO therapies and gene therapy Elevidys.
Nov 04, 2025 • Motley Fool SOMEWHAT-BULLISH
Privium Fund Management Sells Into Strength in Pharma Stock
On November 3, 2025, Privium Fund Management B.V. reported selling 138,263 shares of Arrowhead Pharmaceuticals ( NASDAQ:ARWR ) for an estimated $3.04 million based on the average price for the third quarter of 2025, according to its latest SEC filing.According to its SEC filing dated November 3, ...
Oct 28, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Sentiment Snapshot

Average Sentiment Score:

0.145
50 articles with scored sentiment

Overall Sentiment:

Neutral

ARWR Reported Earnings

Aug 07, 2025
Jun 30, 2025 (Pre market)
-0.4 Surprise
  • Reported EPS: $-1.26
  • Estimate: $-0.86
  • Whisper: —
  • Surprise %: -46.5%
May 12, 2025
Mar 31, 2025 (Pre market)
3.21 Surprise
  • Reported EPS: $2.75
  • Estimate: $-0.46
  • Whisper: —
  • Surprise %: 695.0%
Feb 10, 2025
Dec 31, 2024 (Pre market)
-0.67 Surprise
  • Reported EPS: $-1.39
  • Estimate: $-0.72
  • Whisper: —
  • Surprise %: -92.2%
Nov 26, 2024
Sep 30, 2024 (Pre market)
-0.45 Surprise
  • Reported EPS: $-1.37
  • Estimate: $-0.92
  • Whisper: —
  • Surprise %: -48.6%
Aug 08, 2024
Jun 30, 2024 (Post market)
-0.83 Surprise
  • Reported EPS: $-1.38
  • Estimate: $-0.55
  • Whisper: —
  • Surprise %: -150.9%
May 09, 2024
Mar 31, 2024 (Post market)
-0.86 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-0.16
  • Whisper: —
  • Surprise %: -537.5%
Feb 06, 2024
Dec 31, 2023 (Post market)
-0.42 Surprise
  • Reported EPS: $-1.24
  • Estimate: $-0.82
  • Whisper: —
  • Surprise %: -51.2%
Nov 29, 2023
Sep 30, 2023 (Post market)
-0.42 Surprise
  • Reported EPS: $-1.02
  • Estimate: $-0.60
  • Whisper: —
  • Surprise %: -70.0%
Aug 07, 2023
Jun 30, 2023 (Post market)
-0.31 Surprise
  • Reported EPS: $-0.96
  • Estimate: $-0.65
  • Whisper: —
  • Surprise %: -47.7%

Financials